Last reviewed · How we verify
anti TNFa monoclonal antibody - Infliximab
anti TNFa monoclonal antibody - Infliximab is a Small molecule drug developed by KU Leuven. It is currently in Phase 2 development.
At a glance
| Generic name | anti TNFa monoclonal antibody - Infliximab |
|---|---|
| Sponsor | KU Leuven |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis (PHASE4)
- Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease (PHASE4)
- Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation (NA)
- Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not? (NA)
- Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
- Post-Operative Crohn's Disease Outcome in Children
- De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease (PHASE4)
- Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti TNFa monoclonal antibody - Infliximab CI brief — competitive landscape report
- anti TNFa monoclonal antibody - Infliximab updates RSS · CI watch RSS
- KU Leuven portfolio CI
Frequently asked questions about anti TNFa monoclonal antibody - Infliximab
What is anti TNFa monoclonal antibody - Infliximab?
anti TNFa monoclonal antibody - Infliximab is a Small molecule drug developed by KU Leuven.
Who makes anti TNFa monoclonal antibody - Infliximab?
anti TNFa monoclonal antibody - Infliximab is developed by KU Leuven (see full KU Leuven pipeline at /company/ku-leuven).
What development phase is anti TNFa monoclonal antibody - Infliximab in?
anti TNFa monoclonal antibody - Infliximab is in Phase 2.